Purchase this article with an account.
Guillermo Salcedo, Mariana Harasawa, Raul Velez-Montoya, Marc T Mathias, Frank S Siringo, Jeffrey L Olson, Scott C Oliver, Naresh Mandava, Hugo Quiroz-Mercado; Spectral Domain Optical Coherence Tomographic Analysis Of Non-Occluded Retina in Branch Retinal Vein Occlusion And Its Response to Anti-angiogenic Therapy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1935.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze the remote effect of a branch retinal vein occlusion (BRVO) in the non-occluded retina, and to determine the response it may have with anti-angiogenic therapy. To determine if anti-angiogenic therapy may have an atrophic effect on non-occluded retina. Two alternate hypothesis were stated: There will be a remote effect on the non-occluded retina represented by an increase in thickness and area; Anti-angiogenic therapy will decrease the thickness and area but will not go below baseline when compared to controls, therefore rejecting an atrophic effect.
Retrospective, longitudinal, comparative analysis. Inclusion criteria: patients with BRVO treated with anti-angiogenic therapy. Exclusion criteria: patients with diabetes mellitus and glaucoma. Eyes were divided between an experimental anti-angiogenic group (BRVO eye) and a control group (normal eye). Each eye was analyzed for thickness and area changes. Thickness was observed in 35 consecutive scans of the non-occluded retina for the experimental eyes, and the same corresponding zone was measured in the control eye. Thickness measurements were performed for total retinal thickness (TRT), inner retina thickness (IRT), and outer retina thickness (ORT). Area measurements were done on a high-definition line scan observing the non-occluded retina and using the manual caliper. Area was measured for photoreceptors, choroid and full-retina.
18 eyes of 9 patients were analyzed. The number of scans analyzed for the control group were 1298, for the anti-angiogenic group 1052. The number of area measurements for the control group were 152, while for the anti-angiogenic group 124. Normal distributions were observed in all measurements. The value observed at -3 standard deviations below the mean of the control group was used as the sample mean value for the anti-angiogenic group to determine the probability of having lower thicknesses and areas due to the disease (BRVO) or the effect of the drug. P-values were: TRT: P=0.0119; IRT: P=0.0110; ORT: P=0.0073; Photoreceptor’s Area: P=0.0099; Choroid’s Area: P=<0.0002; Retina’s Area: P=0.009.
Non-occluded retina increases in thickness and area in BRVO. Anti-angiogenic therapy will decrease thickness and area. It is not probable that anti-angiogenic therapy will have an atrophic effect in non-occluded retina.
This PDF is available to Subscribers Only